Chemomab Therapeutics (CMMB) 10-K 30 Mar 22 2021 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)		12 Months Ended
		Dec. 31, 2021	Mar. 24, 2022	Jun. 30, 2021
Document Information [Line Items]
Entity Central Index Key		0001534248
Document Fiscal Period Focus		FY
Amendment Flag		false
Document Type		10-K
Current Fiscal Year End Date		--12-31
Document Fiscal Year Focus		2021
Document Period End Date		Dec. 31, 2021
Document Annual Report		true
Document Transition Report		false
Entity File Number		001-38807
Entity Registrant Name		CHEMOMAB THERAPEUTICS LTD.
Entity Incorporation, State or Country Code		L3
Entity Tax Identification Number		81-3676773
Entity Address, Address Line One		Kiryat Atidim
Entity Address, Address Line Two		Building 7
Entity Address, City or Town		Tel Aviv
Entity Address, Country		IL
Entity Address, Postal Zip Code		6158002
City Area Code		972
Local Phone Number		77-331-0156
Entity Well Known Seasoned Issuer		No
Entity Voluntary Filers		No
Entity Current Reporting Status		Yes
Entity Interactive Data Current		Yes
Entity Filer Category		Non-accelerated Filer
Entity Small Business		true
Entity Emerging Growth Company		true
Entity Ex Transition Period		false
Auditor Attestation Flag		false
Entity Shell Company		false
Entity Public Float				$ 194,646,077
Entity Common Stock, Shares Outstanding			228,090,300
Auditor Name		Somekh Chaikin
Auditor Location		Tel Aviv, Israel
Auditor Firm Id		1057
American Depositary Shares [Member]
Document Information [Line Items]
Title of 12(b) Security		American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share
Trading Symbol		CMMB
Name of Exchange on which Security is Registered		NASDAQ
Ordinary Shares, No Par Value Per Share [Member]
Document Information [Line Items]
Title of 12(b) Security		Ordinary shares, no par value per share
Trading Symbol		n/a
Name of Exchange on which Security is Registered	[1]	NASDAQ
[1]	Not for trading; only in connection with the registration of American Depository Shares.

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 15,186	$ 11,674
Short-term bank deposit	45,975	24
Other receivables and prepaid expenses	1,527	141
Total current assets	62,688	11,839
Non-current assets
Long-term deposits		4
Long-term prepaid expenses	908
Restricted cash	55	53
Property and equipment, net	357	152
Operating lease right-of-use assets	345	428
Total non-current assets	1,665	637
Total assets	64,353	12,476
Current liabilities:
Trade payables	1,336	93
Accrued expenses	555	715
Employee and related expenses	653	438
Operating lease liabilities	106	70
Total current liabilities	2,650	1,316
Non-current liabilities
Non-current operating lease liabilities	237	358
Total non-current liabilities	237	358
Commitments and contingent liabilities
Total liabilities	2,887	1,674
Shareholders' equity:
Ordinary Shares no par value - Authorized: 650,000,000 shares as of December 31, 2021 and 500,000,000 shares as of December 31, 2020; Issued and outstanding: 228,090,300 shares at December 31, 2021 and 9,274,838 shares at December 31, 2020
Additional paid-in capital	97,639	34,497
Accumulated deficit	(36,173)	(23,695)
Total shareholders' equity	61,466	10,802	[1]
Total liabilities and shareholders' equity	$ 64,353	$ 12,476
[1]	Number of shares has been retroactively adjusted to reflect the share reverse split effected on March 16, 2021 (refer to Note 1)

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Common Stock, No Par Value	$ 0	$ 0
Common Stock, Shares Authorized	650,000,000	500,000,000
Common Stock, Shares, Issued	228,090,300	9,274,838
Common Stock, Shares, Outstanding	228,090,300	9,274,838

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020
Operating expenses
Research and development		$ 6,334	$ 4,684
General and administrative		6,033	1,288
Total operating expenses		12,367	5,972
Financing expenses (income), net		111	(21)
Net loss for the year		$ 12,478	$ 5,951
Basic and diluted loss per Ordinary Share	[1]	$ 0.060	$ 0.044
Weighted average number of Ordinary Shares outstanding, basic, and diluted	[1]	207,468,650	136,755,498
[1]	Number of shares has been retroactively adjusted to reflect the share reverse split effected on March 16, 2021 (refer to Note 1)

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($) $ in Thousands		Ordinary shares [Member]		Additional paid in capital [Member]	Accumulated deficit [Member]	Total
Beginning balance at Dec. 31, 2019	[1]			$ 30,117	$ (17,744)	$ 12,373
Beginning balance (in shares) at Dec. 31, 2019	[1]	9,274,838
Share-based compensation				130		130
Issuance of shares				3,000		3,000
Exercise of warrants				1,250		1,250
Net loss for the year					(5,951)	(5,951)
Ending balance at Dec. 31, 2020	[1]			34,497	(23,695)	$ 10,802
Ending balance (in shares) at Dec. 31, 2020		9,274,838	[1]			9,274,838
Share-based compensation				2,019		$ 2,019
Effect of reverse capitalization transaction				2,476		2,476
Effect of reverse capitalization transaction (In shares)		152,299,702
Issuance of shares and warrants, net of issuance costs				58,637		58,637
Issuance of shares and warrants, net of issuance costs (In shares)		66,381,520
Exercise of Options				10		10
Exercise of Options, shares		134,240
Net loss for the year					(12,478)	(12,478)
Ending balance at Dec. 31, 2021				$ 97,639	$ (36,173)	$ 61,466
Ending balance (in shares) at Dec. 31, 2021		228,090,300				228,090,300
[1]	Number of shares has been retroactively adjusted to reflect the share reverse split effected on March 16, 2021 (refer to Note 1)

Statements of Cash flows

Statements of Cash flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net loss for the year	$ (12,478)	$ (5,951)
Adjustments for operating activities:
Depreciation	34	24
Share-based compensation	2,019	130
Change in other receivables and prepaid expenses	(2,058)	(99)
Change in trade payables	1,175	68
Change in accrued expenses	(1,279)	392
Change in employees and related expenses	215	194
Change in leases	(2)
Net cash used in operating activities	(12,374)	(5,242)
Cash flows from investing activities
Investment in deposits	(45,951)	(24)
Long-term lease deposit	4
Sale of asset held for sale	1,000
Purchase of property and equipment	(239)	(38)
Net cash used in investing activities	(45,186)	(62)
Cash flows from financing activities
Cash acquired in Merger	2,427
Exercise of options	10
Exercise of warrants		1,250
Issuance of shares and warrants, net of issuance costs	58,637	3,500
Net cash provided by financing activities	61,074	4,750
Change in cash, cash equivalents and restricted cash	3,514	(554)
Cash, cash equivalents and restricted cash at beginning of the year	11,727	12,281
Cash, cash equivalents and restricted cash at end of the year	15,241	11,727
Significant non- cash transaction:
Right-of-use asset recognized with corresponding lease liability	345	233
Liabilities assumed, net of non-cash assets received in Merger	$ 49

General

General	12 Months Ended
	Dec. 31, 2021
NATURE OF OPERATIONS
General	Note 1 - General 1. Chemomab Therapeutics Ltd. (hereinafter - "the Company") is an Israeli based company incorporated under the laws The Company is a clinical-stage biotech company discovering and developing innovative therapeutics for conditions with high-unmet medical need that involve inflammation and fibrosis. 2. The Company currently has no products approved for sale. The Company’s operations are funded primarily by its 3. Since January 2020, the COVID-19 outbreak has dramatically expanded into a worldwide pandemic creating Chemomab's clinical trial sites have been affected by the COVID-19 pandemic, and as a result, enrollment rate of patients to Chemomab’s clinical trials has been affected. There might be additional delays in the enrollment for Chemomab’s CM-101 phase 2 trials. In addition, after enrollment in these trials, patients might drop out of Chemomab’s trials because of the COVID-19 possible implications. Based on management’s assessment, the extent to which the coronavirus will further impact Chemomab’s operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration and severity of the outbreak, and the actions that may be required to contain the coronavirus or treat its impact. Chemomab’s is carefully monitoring the restrictions due to the COVID-19 outbreak and will adjust activities accordingly. 4. On December 14, 2020, the Company (formerly known as Anchiano Therapeutics Ltd.) entered into an Agreement and At the Effective Time(a) each Chemomab Ltd. ordinary share outstanding immediately prior to the Effective Time was converted solely into number of American Depository Shares equal to the exchange ratio described in the Merger Agreement, and each outstanding Chemomab Ltd. option was assumed by the Company, based on the same exchange ratio. Under the exchange ratio formula in the Merger Agreement, immediately following the closing of the Merger (the “Closing”), the former Chemomab Ltd security holders immediately before the Merger owned approximately 90% of the aggregate number of the outstanding securities of the Company, and the securityholders of the Company immediately prior to the Merger owned approximately 10% of the number of issued and outstanding ordinary shares of the Company (all on a fully diluted basis). F - 7 Chemomab Therapeutics Ltd. and its subsidiaries Notes to the Financial Statements as at December 31, 2021   Note 1 - General. (cont’d) For accounting purposes, Chemomab Ltd. is considered to have acquired the Company based upon the terms of the Merger as well as other factors including; (i) Chemomab Ltd.’s former shareholders owned approximately 90% of the combined Company’s outstanding ordinary shares immediately following the closing of the Merger, and (ii) Chemomab Ltd. Management holds key management positions of the combined Company. The Merger has been accounted for as an asset acquisition (reverse recapitalization transaction) rather than a business combination, as the assets acquired, and the liabilities assumed by Chemomab Ltd. do not meet the definition of a business under U.S. GAAP. The net assets acquired in connection with the Merger were recorded at their estimated acquisition date fair market value as of March 16, 2021, the date of completion of the Merger. In connection with the Merger, and following the effective time of the Merger, the Company effected a reverse share split of the Company’s ordinary shares at a ratio of 4:1 (the “Reverse Split”) and increased the number of ordinary shares underlying each American Depositary Share (“ADS”) from 5 to 20 ordinary shares. At the effective time of the Merger, each Chemomab Ltd. ordinary shares outstanding immediately prior to the effective time of the Merger automatically converted into the right to receive approximately 12.86 ADSs, each representing 20 ordinary shares of the Company, and a warrant to purchase additional ADSs that may become exercisable only under certain circumstances. The exchange ratio was calculated by a formula that was determined through arms-length negotiations between the Company and Chemomab Ltd. The combined Company assumed all of the outstanding options of Chemomab Ltd., vested and not vested, under the Chemomab Share Incentive Plan (the “2015 Plan”), with such options representing the right to purchase a number of ADSs equal to approximately 12.86 multiplied by the number of Chemomab Ltd. ordinary shares previously represented by such options. The following table summarizes the net assets acquired based on their estimated fair values as of March 16, 2021, immediately prior to completion of the Merger (in USD thousands): Cash and cash equivalents 2,427 Asset held for sale 1,000 Prepaid and other assets 236 Accrued liabilities (1,187 ) Net acquired assets 2,476

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 - Summary of Significant Accounting Policies A. Basis of Preparation The financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S GAAP”). B. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. C. Foreign currency The currency of the primary economic environment in which the operations of the Company are conducted is the U.S. dollar (“dollar” or “$”), thus; the dollar is the functional currency of the Company. The transactions and balances of the Company denominated in U.S. dollars are presented at their original amounts as the U.S. dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future. Monetary assets and liabilities denominated in a non-U.S. dollar currency are translated using the current exchange rate and nonmonetary assets and liabilities and capital accounts denominated in a non-U.S. dollar currency are translated using historical exchange rates. Statements of operations accounts denominated in a non-U.S. dollar currency are translated using the exchange rates in effect on the transaction dates, except for depreciation, which is translated using historical exchange rate. D. Cash and cash equivalents Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at the date acquired. E. Restricted cash Restricted cash is primarily invested in highly liquid deposits. These deposits were used to secure office rent payments. F. Property and equipment Property and equipment are stated at cost less accumulated depreciation. Maintenance and repair expenses are charged to operation as incurred. Depreciation is calculated on the straight-line method based on the estimated useful lives of the assets and commences once the assets are ready for their intended use. Annual rates at depreciation are as follows: % Computers 33 Laboratory equipment 10 Furniture and equipment 7 Leasehold improvement - over the shorter of the lease term or the estimated useful life of the improvement F - 9 Chemomab Therapeutics Ltd. and its subsidiaries Notes to the Financial Statements as at December 31, 2021   Note 2 - Summary of Significant Accounting Policies (cont’d) G. Impairment of long-lived assets The Company’s property and equipment are reviewed for impairment in accordance with ASC 360, “Property and Equipment”, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less selling costs. During the periods ended December 31, 2021 and 2020, no impairment losses have been recorded. H. Research and Development Research and development costs are charged to operations as incurred. Most of the research and development expenses are for subcontractors and wages. L. Income taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the income taxes expense. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized. J. Fair value of financial instruments ASC 820, Fair Value Measurements and Disclosures, relating to fair value measurements, defines fair value and established a framework for measuring fair value. The ASC 820 fair value hierarchy distinguishes between market participant assumptions developed based on market data obtained from sources independent of the reporting entity and the reporting entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price. F - 10 Chemomab Therapeutics Ltd. and its subsidiaries Notes to the Financial Statements as at December 31, 2021   Note 2 - Summary of Significant Accounting Policies (cont’d) J. Fair value of financial instruments (cont’d) In addition, the fair value of assets and liabilities should include consideration of non-performance risk, which for the liabilities described below includes the Company’s own credit risk. As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. The carrying amounts of cash and cash equivalents trade payables, other receivables and accrued expenses approximate their fair value due to the short-term maturity of such instruments. The fair value of long-term restricted deposits and restricted cash also approximates their carrying value, since they bear interest at rates close to the prevailing market rates. None of the Company’s non - K. Share-based compensation The Company accounts for share-based compensation as an expense in the financial statements based on ASC 718. All awards are equity classified and therefore such costs are measured at the grant date fair value of the award and graded vesting attribution approach to recognize compensation cost over the vesting period. The Company recognizes compensation cost for an award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant-date value of such award that is vested at that date. The fair value for the Company’s stock options granted to employees, consultants and directors was estimated using Black-Scholes option-pricing model at the grant date, using the inputs detailed in Note 8(C). The Company has historically not paid dividends and has no foreseeable plans to pay dividends. L. Government-sponsored research and development Chemomab records grants received from the office of the Israel Innovation Authority (the “IIA”) as a liability, if it is probable that the Chemomab will have to repay the grants received. If it is not probable that the grants will be repaid, Chemomab records the grants as a reduction to research and development expenses. F - 11 Chemomab Therapeutics Ltd. and its subsidiaries Notes to the Financial Statements as at December 31, 2021   Note 2 - Summary of Significant Accounting Policies (cont’d) M. Severance pay Pursuant to Section 14 of the Severance Compensation Law, 1963 ("Section 14"), all employees of the Company are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made on their behalf with insurance companies. Upon release of the policy to the employee, no additional liability exists between the parties regarding the matter of severance pay and no additional payments shall be made by the Company to the employee. This plan has been accounted for as a defined contribution plan. Severance costs amounted to approximately 116 and 77 thousand USD for the year ended December 31, 2021 and 2020, respectively. N. Concentrations of credit risk: Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. Cash and cash equivalents and short term deposits are invested in banks in Israel. Management believes that the financial institutions that hold the Company’s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments. The Company have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements. O. Leases Under Topic 842, the Company determines if an arrangement is a lease at inception. ROU assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company's incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be 5% in 2021. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. When determining the probability of exercising such options, the Company considers contract-based, asset-based, entity-based, and market-based factors. For leases agreements, the Company has elected the practical expedient to account for the lease and non-lease maintenance components as a single lease component. Therefore, for those leases, the lease payments used to measure the lease liability include all the fixed consideration in the contract. The Company's lease agreements generally do not contain any residual value guarantees or restrictive covenants. F - 12 Chemomab Therapeutics Ltd. and its subsidiaries Notes to the Financial Statements as at December 31, 2021   Note 2 - Summary of Significant Accounting Policies (cont’d) O. Leases (cont’d) For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. ROU assets for operating leases are periodically reduced by impairment losses. The Company uses the long-lived assets impairment guidance in ASC Subtopic 360-10, Property, Plant, and Equipment – Overall, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize. See Note 2(G). P. Principles of consolidation The consolidated financial statements include the accounts of the Company and the Subsidiary. Intercompany balances and transactions have been eliminated in consolidation. Q. Earnings per ordinary share Basic earnings per ordinary share is calculated using only weighted average ordinary shares outstanding. Diluted earnings per share, if relevant, gives effect to dilutive potential ordinary shares outstanding during the year. Such dilutive shares consist of incremental shares, using the treasury stock method, from the assumed exercise of share options.

Cash and Cash Equivalents

Cash and Cash Equivalents	12 Months Ended
	Dec. 31, 2021
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents	Note 3 - Cash and Cash Equivalents December 31, December 31, 2021 2020 USD thousands USD thousands In NIS 1,116 95 In USD 10,720 11,526 In other currencies 3,350 53 15,186 11,674

Other Receivables and Prepaid E

Other Receivables and Prepaid Expenses	12 Months Ended
	Dec. 31, 2021
Prepaid Expense and Other Assets [Abstract]
Other Receivables and Prepaid Expenses	Note 4 - Other Receivables and Prepaid Expenses December 31, December 31, 2021 2020 USD thousands USD thousands Government institutions 179 74 Prepaid expenses 1,348 67 1,527 141

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Note 5 - Property and Equipment, Net December 31, December 31, 2021 2020 USD thousands USD thousands Cost: Computers 43 31 Furniture and equipment 27 16 Laboratory equipment 364 159 Website development 14 14 Leasehold improvements 16 5 464 225 Less - accumulated depreciation ( 107 ) (73 ) 357 152

Leases

Leases	12 Months Ended
	Dec. 31, 2021
Lessee Disclosure [Abstract]
Leases	Note 6 - Leases On May 10, 2020, Chemomab entered into an office and lab space lease agreement (hereinafter – “The Agreement” .(According to the Agreement, Chemomab will rent space in Atidim Park, Tel-Aviv through May 2023 On October 24, 2021, Chemomab signed an amendment to the Agreement ("The Amendment"). According to the Amendment, On December 12, 2021 Chemomab returned the previous office and lab space to the property owner and rented a larger space in Atidim Park Tel-Aviv, through October 2024 The above operating leases are included in “Operating lease right-of-use assets” on the Company’s Consolidated Balance sheets as of December 31, 2021 and 2020 and represent the Company’s right to use the underlying asset for the lease term. The Company’s obligations to pay lease payments are included in the current liabilities as “Operating lease liabilities” and in the non-current liabilities as “Non-current operating lease liabilities” on the Company’s Consolidated Balance sheets as of December 31, 2021 and 2020. Based on the present value of the lease payments for the remaining lease term of the Company’s existing lease agreement, the Company recognized operating right-of-use assets and operating lease liabilities of approximately USD 345 thousand on December 12, 2021. During the years ended December 31, 2021 and 2020, the Company recognized an increase in right of use assets of USD 345 thousand and USD 500 thousand, respectively. As of December 31, 2021, operating right-of-use assets and operating lease liabilities were USD 345 thousand and USD 343 thousand, respectively. F - 14 Chemomab Therapeutics Ltd. and its subsidiaries Notes to the Financial Statements as at December 31, 2021   Note 6 - Leases (cont’d) As most of the Chemomab’s leases do not provide an implicit rate, Chemomab uses its incremental borrowing rate based on the information available at the commencement date of each lease in determining the present value of lease payments. Chemomab’s incremental borrowing rate is a hypothetical rate based on its estimation of what its credit rating would be the rate was5.2% in both 2021 and 2020. Maturities of lease liabilities under noncancellable leases as of December 31, 2021, are as follows: (in thousands): 2022 121 2023 133 2024 117 Total future minimum lease payments 371 Less imputed interest: ( 28 ) Present value of operating lease liabilities 343

Commitments and Contingent Liab

Commitments and Contingent Liabilities	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingent Liabilities	Note 7 - Commitments and Contingent Liabilities A. Exclusive License Agreement (hereinafter- “the License Agreement”) In December 2011, Chemomab entered into a License Agreement with the Medical Research, Infrastructure, Health Services Fund of the Tel-Aviv Souraski Medical Center (“Fund”), pursuant to which it was granted with an exclusive license to certain inventions (as defined in the License Agreement) including patents, knowhow and products and the right to sublicense to third parties the rights granted, pursuant to and subject to certain terms and limitation fully set in the License Agreement. Chemomab has agreed to pay the Fund a non-refundable and non-creditable sublicense fees as a percentage of all Attributed Income (as such term defined in the License Agreement), and shall further pay the Fund royalties from sales made by sublicensee; (i) Royalties in percentage of the Net sales or Service Income (as defined in the License Agreement), subject to In addition, with respect to each Licensed Product (as defined therein), Chemomab has agreed to pay the Fund (a) USD 100 thousand upon submission of a New Drug Application (“NDA”), Biological License Application (“BLA”) or equivalent for each Licensed Product to the United States Food and Drug Administration (“FDA”), USD 100 thousand upon submission of similar application for each Licensed Product to an equivalent foreign regulatory agency in Europe and one hundred thousand dollars upon submission of similar application for each Licensed Product to an equivalent foreign regulatory agency in Asia. Payment in the aggregate shall not be more than USD 300 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once; (b) USD 200 thousand upon the grant of FDA or equivalent agency marketing approval in Europe and/or Asia for each Licensed Product. Payment in the aggregate shall not be more than USD 600 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once. As of December 31, 2021 no payments were made to the Fund. F - 15 Chemomab Therapeutics Ltd. and its subsidiaries Notes to the Financial Statements as at December 31, 2021   Note 7 - Commitments and Contingent Liabilities (cont’d) A. Exclusive License Agreement (hereinafter- “the License Agreement”) (cont’d) In addition to the payments described above, upon the occurrence of either (i) closing of a public offering of the ordinary shares of Chemomab; or (ii) a Change of Control Transaction, Chemomab shall pay the Fund a cash payment equal to one percent (1%) of the proceeds raised by Chemomab in its initial public offering, or 1% of the consideration received by Chemomab or its shareholders at the closing of a Change of Control Transaction (after deduction of amounts paid as liquidation preference to the shareholders of Chemomab on account of their investment in Chemomab , if any), but in any event not more than USD 3,000 thousand. B. Chemomab partially financed its research and development expenditures under programs sponsored by the Israel In return for the IIA’s participation, Chemomab is committed to pay royalties at rate of 3% of sales of the developed product (linked to U.S. dollar), up to 100% of the amount of grants received (100% plus interest at LIBOR). Chemomab did not receive any grants from the IIA in the years ended December 31, 2021, and 2020. Since Chemomab ’s incorporation through December 31, 2021 Chemomab received USD 1,227 thousand from the IIA, which were recognized as a reduction of research and development expenses. As of December 31, 2021, Chemomab has no commitment for royalties payable. In addition, the IIA may impose certain conditions to transfer technology or development out of Israel. C. In June 2015, Chemomab entered into a license agreement with subcontractor (“the Subcontractor”), under which the F - 16 Chemomab Therapeutics Ltd. and its subsidiaries Notes to the Financial Statements as at December 31, 2021   Note 7 - Commitments and Contingent Liabilities (cont’d) C. (cont’d) During 2021 and 2020, Chemomab recorded expenses related to the above agreements in the amounts of USD 2,590 thousand and USD 1,177 thousand, respectively. The expenses were recorded under research and development expenses. D. In May 2020, Chemomab executed a lien bank deposit of NIS As of December 31, 2021 the bank restricted deposit amount was USD 55 thousand. In 2022, the 2020 Lien was canceled and Chemomab executed a substitute lien bank deposit of NIS 269 thousand (approximately USD 86 thousand) for the benefit of securing the lease payments under the Amendment to the lease agreement described in Note 6.

Share Capital

Share Capital	12 Months Ended
	Dec. 31, 2021
Stockholders' Equity Note [Abstract]
Share Capital	Note 8 - Share Capital A. Right attached to shares Ordinary shares All of the issued and outstanding ordinary shares of the Company are duly authorized, validly issued, fully paid and non-assessable. The ordinary are not redeemable, and each ordinary share is entitled to one vote. The holders of the ordinary shares have the right to vote and participate in shareholders' meetings, the right to receive profits, and the right to participate in the accumulated earnings when the Company is dissolved. 1. Voting The holders of ordinary shares are entitled to vote on all matters submitted to shareholders for a vote. 2. Dividends The holders of the ordinary shares are entitled to receive dividends, when and as declared by the Board of Directors, and out of funds legally available. Since its inception, the Company has not declared any dividends. B. Financing rounds 1. In June 2015, September 2015 and November 2015, Chemomab entered into an agreement with investors according to 2. During June to December 2020, the Company's investors exercised the warrants for a total consideration of F - 17 Chemomab Therapeutics Ltd. and its subsidiaries Notes to the Financial Statements as at December 31, 2021   Note 8 - Share Capital (cont’d) B. Financing rounds (cont’d) 3. In September 2019, Chemomab Ltd entered into share purchase agreement with current and new investors (hereinafter 4. In November 2019 Chemomab entered into a joinder agreement to 2019 SPA, pursuant to which it issued and sold to 5. In May 2020, Chemomab entered a joinder agreement to 2019 SPA, pursuant to which Chemomab issued 6. In connection with the Merger, on March 15, 2021, the Company entered into Securities Purchase Agreements with 7. On April 30, 2021, the Company entered into an At the Market Offering Agreement (the “ATM Agreement”) with C. Share-based compensation (1) Share-based compensation plan: The Company maintains (i) the 2011 Share Option Plan (the “2011 Plan”), (ii) the 2017 Equity-Based Incentive Plan (the “2017 Plan”) and (iii) the Chemomab 2015 Share Incentive Plan (the “2015 Plan”),  which was assumed by the Company from Chemomab Ltd. the effectiveness of the Merger. At that time, outstanding options under the 2015 Plan became exercisable for such number of ADSs of the Company as was determined based on the exchange ratio in the Merger Agreement, with a reciprocal adjustment to exercise price. As of December 31, 2021, a total of 1,422,153 of our ADSs were reserved for issuance under the 2015 Plan, of which 73,776 ADSs had been issued pursuant to previous exercises options, and 1,326,723 ADSs were issuable under outstanding options. Of such outstanding options, options to purchase 452,230 ADSs had vested and were exercisable as of that date, with a weighted average exercise price of USD 2.75 per ADS. During the year ended December 31, 2021 options to purchase 35,653 ADS were canceled as per the request of an optionee F - 18 Chemomab Therapeutics Ltd. and its subsidiaries Notes to the Financial Statements as at December 31, 2021   Note 8 - Share Capital (cont’d) C. Share-based compensation (cont’d) (2) The expenses that were recognized in the consolidated statements of operations for services received from employees Year ended Year ended December 31, December 31, 2021 2020 USD thousands USD thousands Research and development 137 84 General and administrative 1,882 46 Total share-based compensation expenses 2,019 130 (3) The number and weighted average exercise price of options are as follows: Weighted average exercise price Number of options Weighted average remaining contractual life (in years) Weighted average exercise price Number of options Weighted average remaining contractual life (in years) 2021 2021 2021 2020 2020 2020 Outstanding at January 1 0.07 10,455,580 7.8 0.07 8,072,704 8.09 Acquired in Merger 609,535 Exercise 0.08 ( 134,220 ) - - - - Forfeited 1.25 ( 1,712,275 ) - 0.07 (10,804 ) - Granted 0.62 17,784,640 9.79 0.08 2,393,680 9.77 Outstanding at December 31 0.38 27,003,260 8.12 0.07 10,455,580 7.8 (4) Fair value measurement: The fair value of the options is measured at the grant date using the Black-Scholes Option pricing model and the assumptions used to calculate the fair value of the options are as follows: 2021 grants Weighted average share price (in U.S. dollar) (a) 9.44 - 27.26 Exercise price (in U.S. dollar) 9.44 - 27.26 Expected life of options (in years) (b) 5.73 - 6.28 Expected volatility (c) 65.93 %- 70.88 % Risk-free interest rate (d) 1.36 %- 1.64 % Dividend yield 0 % F - 19 Chemomab Therapeutics Ltd. and its subsidiaries Notes to the Financial Statements as at December 31, 2021   Note 8 - Share Capital (cont’d) C. Share-based compensation (cont’d) (a) The weighted average share price is based on the Company’s ordinary share valuation as at the grant date. (b) Expected life for the periods presented was determined according to the simplified method since, at the date of (c) Expected volatility is based on historical volatility over the most recent period commensurate with the expected (d) The risk-free rate for the expected term of the options is based on the Black-Scholes option-pricing model on the

Research and Development

Research and Development	12 Months Ended
	Dec. 31, 2021
Research and Development [Abstract]
Research and Development	Note 9 - Research and Development Year ended Year ended December 31, December 31, 2021 2020 USD thousands USD thousands Consultants and subcontractors 3,894 3,079 Salaries and related expenses 1,789 1,158 Rent and maintenance 114 106 Share-based compensation 137 84 Other expenses 400 257 6,334 4,684

General and Administrative

General and Administrative	12 Months Ended
	Dec. 31, 2021
General and Administrative Expense [Abstract]
General and Administrative	Note 10 - General and Administrative Year ended Year ended December 31, December 31, 2021 2020 USD thousands USD thousands Salaries and related expenses 943 334 Professional services 1,695 828 Share-based compensation 1,882 46 Fees to Directors 244 - Insurance 1,024 6 Rent and maintenance 29 24 Other expenses 216 50 6,033 1,288

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Note 11 - Income Taxes A. Tax rates Ordinary taxable income in Israel is subject to a corporate tax rate of 23%. The Company’s US subsidiary, Chemomab Therapeutics Inc. ("Chemomab Inc.) is taxed separately under the U.S. tax laws. Chemomab Inc. is subject to a federal flat tax rate of 21% and state tax as applicable. Capital gain is subject to capital gain tax according to the corporate tax rate in the year the assets are sold. B. Tax assessments As of December 31, 2021, the Company’s tax reports through December 31, 2016 are considered closed to audit inspections by the Israeli Tax Authority (“ITA”) due to statute of limitation rules effective in Israel. The Company has not yet been assessed by the ITA since inception. C. Losses for tax purposes carried forward to future years As of December 31, 2021, the Company and its subsidiaries had approximately $143 million (approximately $21 million as of December 31, 2020) of net operating loss carryforwards which are available to reduce future taxable income with no limitation on the period of use. F - 21 Chemomab Therapeutics Ltd. and its subsidiaries Notes to the Financial Statements as at December 31, 2021   Note 11 - Income Taxes (cont’d) D. Deferred taxes In respect of: December 31, December 31, 2021 2020 USD thousands USD thousands Net operating loss carry-forwards 33,396 4,874 Share-based compensation expense 1,147 57 Research and development costs 1,449 1,244 Other 38 25 Gross deferred tax assets 36,030 6,200 Less - Valuation allowance ( 36,030 ) (6,200) Net deferred tax assets - - In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. A valuation allowance is provided when it is more likely than not that the deferred tax assets will not be realized. The Company has established a valuation allowance to offset deferred tax assets on December 31, 2021 and 2020 due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. The net change in the total valuation allowance for the year ended at December 31, 2021 was an increase of approximately USD 2.6 million. E. Roll forward of valuation allowance Balance at January 1, 2020 $ 4,248 Currency transaction loss 583 Income tax expense 1,369 Balance at December 31, 2020 $ 6,200 Currency transaction loss 2,425 Tax assets acquired through merger 24,535 Income tax expense 2,870 Balance at December 31, 2021 $ 36,030 F - 22 Chemomab Therapeutics Ltd. and its subsidiaries Notes to the Financial Statements as at December 31, 2021   Note 11 - Income Taxes (cont’d) F. Reconciliation of theoretical income tax expense to actual income tax expense A reconciliation of the Company’s theoretical income tax expense to actual income tax expense is as follows: December 31, December 31, 2021 2020 USD thousands USD thousands Loss before income taxes ( 12,478 ) (5,951 ) Statutory tax rate 23 % 23 % Theoretical tax benefit ( 2,870 ) (1,369 ) Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards 2,870 1,369 Actual income tax expense - - G. Accounting for uncertainty in income taxes For the year ended December 31, 2021, the Company did not have any unrecognized tax benefits and does not expect that the amount of unrecognized tax benefits will change significantly within the next 12 months. The Company’s accounting policy is to accrue interest and penalties related to unrecognized tax benefits as a component of income tax expense.

Related Parties Balances and Tr

Related Parties Balances and Transactions	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Parties Balances and Transactions	Note 12 - Related Parties Balances and Transactions A. Balances with Related Parties: The following Related Party payables are included in the consolidated Balance Sheets: December 31, December 31, 2021 2020 USD thousands USD thousands Employee and related expenses 278 214 Accrued expenses 72 3 350 217 F - 23 Chemomab Therapeutics Ltd. and its subsidiaries Notes to the Financial Statements as at December 31, 2021   Note 12 - Related Parties Balances and Transactions (cont'd) B. Transactions with Related Parties: The following transactions with related parties are included in the consolidated Statements of Operations: Year ended Year ended December 31, December 31, 2021 2020 USD thousands USD thousands Salaries and related expenses 1,255 605 Share-based payments 1,775 91 Professional Services 244 45 Research and development 36 36 3,310 777

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Ordinary Shareholders	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Net Loss Per Share Attributable to Ordinary Shareholders	Note 13 - Net Loss Per Share Attributable to Ordinary Shareholders Basic net loss per share is computed by dividing the net loss available to common stockholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares of were dilutive. Diluted net loss per share is the same as basic net loss per share of ordinary share, as the effect of potentially dilutive securities is antidilutive. The following table sets forth the computation of basic and diluted net loss per share attributable to ordinary shareholders for the periods presented: Year ended Year ended December 31 December 31 2021 2020 In USD thousands, except share and per share data Numerator: Net loss 12,478 5,951 Denominator: Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted 207,468,650 136,755,498 Net loss per share attributable to ordinary shareholders, basic and diluted 0.060 0.044 F - 24 Chemomab Therapeutics Ltd. and its subsidiaries Notes to the Financial Statements as at December 31, 2021   Note 13 - Net Loss Per Share Attributable to Ordinary Shareholders (cont'd) The potential number of weighted-average ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented since including them would have been anti-dilutive are as follows: Year ended Year ended December 31 December 31 2021 2020 Number of shares Outstanding options to purchase ordinary shares 27,003,260 10,455,580

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of presentation	A. Basis of Preparation The financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S GAAP”).
Use of estimates	B. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.
Functional currency	C. Foreign currency The currency of the primary economic environment in which the operations of the Company are conducted is the U.S. dollar (“dollar” or “$”), thus; the dollar is the functional currency of the Company. The transactions and balances of the Company denominated in U.S. dollars are presented at their original amounts as the U.S. dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future. Monetary assets and liabilities denominated in a non-U.S. dollar currency are translated using the current exchange rate and nonmonetary assets and liabilities and capital accounts denominated in a non-U.S. dollar currency are translated using historical exchange rates. Statements of operations accounts denominated in a non-U.S. dollar currency are translated using the exchange rates in effect on the transaction dates, except for depreciation, which is translated using historical exchange rate.
Cash and cash equivalents	D. Cash and cash equivalents Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at the date acquired.
Restricted cash	E. Restricted cash Restricted cash is primarily invested in highly liquid deposits. These deposits were used to secure office rent payments.
Property and equipment	F. Property and equipment Property and equipment are stated at cost less accumulated depreciation. Maintenance and repair expenses are charged to operation as incurred. Depreciation is calculated on the straight-line method based on the estimated useful lives of the assets and commences once the assets are ready for their intended use. Annual rates at depreciation are as follows: % Computers 33 Laboratory equipment 10 Furniture and equipment 7 Leasehold improvement - over the shorter of the lease term or the estimated useful life of the improvement
Impairment of long-lived assets	G. Impairment of long-lived assets The Company’s property and equipment are reviewed for impairment in accordance with ASC 360, “Property and Equipment”, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less selling costs. During the periods ended December 31, 2021 and 2020, no impairment losses have been recorded.
Research and development	H. Research and Development Research and development costs are charged to operations as incurred. Most of the research and development expenses are for subcontractors and wages.
Income taxes	L. Income taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the income taxes expense. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized.
Fair value of financial instruments	J. Fair value of financial instruments ASC 820, Fair Value Measurements and Disclosures, relating to fair value measurements, defines fair value and established a framework for measuring fair value. The ASC 820 fair value hierarchy distinguishes between market participant assumptions developed based on market data obtained from sources independent of the reporting entity and the reporting entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price. F - 10 Chemomab Therapeutics Ltd. and its subsidiaries Notes to the Financial Statements as at December 31, 2021   Note 2 - Summary of Significant Accounting Policies (cont’d) J. Fair value of financial instruments (cont’d) In addition, the fair value of assets and liabilities should include consideration of non-performance risk, which for the liabilities described below includes the Company’s own credit risk. As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. The carrying amounts of cash and cash equivalents trade payables, other receivables and accrued expenses approximate their fair value due to the short-term maturity of such instruments. The fair value of long-term restricted deposits and restricted cash also approximates their carrying value, since they bear interest at rates close to the prevailing market rates. None of the Company’s non -
Share-based compensation	K. Share-based compensation The Company accounts for share-based compensation as an expense in the financial statements based on ASC 718. All awards are equity classified and therefore such costs are measured at the grant date fair value of the award and graded vesting attribution approach to recognize compensation cost over the vesting period. The Company recognizes compensation cost for an award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant-date value of such award that is vested at that date. The fair value for the Company’s stock options granted to employees, consultants and directors was estimated using Black-Scholes option-pricing model at the grant date, using the inputs detailed in Note 8(C). The Company has historically not paid dividends and has no foreseeable plans to pay dividends.
Government-sponsored research and development	L. Government-sponsored research and development Chemomab records grants received from the office of the Israel Innovation Authority (the “IIA”) as a liability, if it is probable that the Chemomab will have to repay the grants received. If it is not probable that the grants will be repaid, Chemomab records the grants as a reduction to research and development expenses.
Severance pay	M. Severance pay Pursuant to Section 14 of the Severance Compensation Law, 1963 ("Section 14"), all employees of the Company are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made on their behalf with insurance companies. Upon release of the policy to the employee, no additional liability exists between the parties regarding the matter of severance pay and no additional payments shall be made by the Company to the employee. This plan has been accounted for as a defined contribution plan. Severance costs amounted to approximately 116 and 77 thousand USD for the year ended December 31, 2021 and 2020, respectively.
Concentration of credit risks	N. Concentrations of credit risk: Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. Cash and cash equivalents and short term deposits are invested in banks in Israel. Management believes that the financial institutions that hold the Company’s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments. The Company have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.
Leases	O. Leases Under Topic 842, the Company determines if an arrangement is a lease at inception. ROU assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company's incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be 5% in 2021. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. When determining the probability of exercising such options, the Company considers contract-based, asset-based, entity-based, and market-based factors. For leases agreements, the Company has elected the practical expedient to account for the lease and non-lease maintenance components as a single lease component. Therefore, for those leases, the lease payments used to measure the lease liability include all the fixed consideration in the contract. The Company's lease agreements generally do not contain any residual value guarantees or restrictive covenants. F - 12 Chemomab Therapeutics Ltd. and its subsidiaries Notes to the Financial Statements as at December 31, 2021   Note 2 - Summary of Significant Accounting Policies (cont’d) O. Leases (cont’d) For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. ROU assets for operating leases are periodically reduced by impairment losses. The Company uses the long-lived assets impairment guidance in ASC Subtopic 360-10, Property, Plant, and Equipment – Overall, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize. See Note 2(G).
Principles of consolidation	P. Principles of consolidation The consolidated financial statements include the accounts of the Company and the Subsidiary. Intercompany balances and transactions have been eliminated in consolidation.
Earnings per ordinary share	Q. Earnings per ordinary share Basic earnings per ordinary share is calculated using only weighted average ordinary shares outstanding. Diluted earnings per share, if relevant, gives effect to dilutive potential ordinary shares outstanding during the year. Such dilutive shares consist of incremental shares, using the treasury stock method, from the assumed exercise of share options.

General (Tables)

General (Tables)	12 Months Ended
	Dec. 31, 2021
NATURE OF OPERATIONS
Schedule of net assets acquired based on their estimated fair value	The following table summarizes the net assets acquired based on their estimated fair values as of March 16, 2021, immediately prior to completion of the Merger (in USD thousands): Cash and cash equivalents 2,427 Asset held for sale 1,000 Prepaid and other assets 236 Accrued liabilities (1,187 ) Net acquired assets 2,476

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of Annual rate of Deprecation	Annual rates at depreciation are as follows: % Computers 33 Laboratory equipment 10 Furniture and equipment 7 Leasehold improvement - over the shorter of the lease term or the estimated useful life of the improvement

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	12 Months Ended
	Dec. 31, 2021
Cash and Cash Equivalents [Abstract]
Schedule of components of cash and cash equivalents	December 31, December 31, 2021 2020 USD thousands USD thousands In NIS 1,116 95 In USD 10,720 11,526 In other currencies 3,350 53 15,186 11,674

Other Receivables and Prepaid_2

Other Receivables and Prepaid Expenses (Tables)	12 Months Ended
	Dec. 31, 2021
Prepaid Expense and Other Assets [Abstract]
Schedule of other accounts receivable and prepaid expenses	December 31, December 31, 2021 2020 USD thousands USD thousands Government institutions 179 74 Prepaid expenses 1,348 67 1,527 141

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of Property And Equpment, Net	December 31, December 31, 2021 2020 USD thousands USD thousands Cost: Computers 43 31 Furniture and equipment 27 16 Laboratory equipment 364 159 Website development 14 14 Leasehold improvements 16 5 464 225 Less - accumulated depreciation ( 107 ) (73 ) 357 152

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Lessee Disclosure [Abstract]
Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases	Maturities of lease liabilities under noncancellable leases as of December 31, 2021, are as follows: (in thousands): 2022 121 2023 133 2024 117 Total future minimum lease payments 371 Less imputed interest: ( 28 ) Present value of operating lease liabilities 343

Share Capital (Tables)

Share Capital (Tables)	12 Months Ended
	Dec. 31, 2021
Stockholders' Equity Note [Abstract]
Summary of the effect of share-based compensation on the statements of operations	(2) The expenses that were recognized in the consolidated statements of operations for services received from employees Year ended Year ended December 31, December 31, 2021 2020 USD thousands USD thousands Research and development 137 84 General and administrative 1,882 46 Total share-based compensation expenses 2,019 130
Summary of number and weighted average exercise prices of option	(3) The number and weighted average exercise price of options are as follows: Weighted average exercise price Number of options Weighted average remaining contractual life (in years) Weighted average exercise price Number of options Weighted average remaining contractual life (in years) 2021 2021 2021 2020 2020 2020 Outstanding at January 1 0.07 10,455,580 7.8 0.07 8,072,704 8.09 Acquired in Merger 609,535 Exercise 0.08 ( 134,220 ) - - - - Forfeited 1.25 ( 1,712,275 ) - 0.07 (10,804 ) - Granted 0.62 17,784,640 9.79 0.08 2,393,680 9.77 Outstanding at December 31 0.38 27,003,260 8.12 0.07 10,455,580 7.8
Summary of assumptions used to calculate the fair value of the options	The fair value of the options is measured at the grant date using the Black-Scholes Option pricing model and the assumptions used to calculate the fair value of the options are as follows: 2021 grants Weighted average share price (in U.S. dollar) (a) 9.44 - 27.26 Exercise price (in U.S. dollar) 9.44 - 27.26 Expected life of options (in years) (b) 5.73 - 6.28 Expected volatility (c) 65.93 %- 70.88 % Risk-free interest rate (d) 1.36 %- 1.64 % Dividend yield 0 %

Research and Development (Table

Research and Development (Tables)	12 Months Ended
	Dec. 31, 2021
Research and Development [Abstract]
Schedule of Research and Development	Year ended Year ended December 31, December 31, 2021 2020 USD thousands USD thousands Consultants and subcontractors 3,894 3,079 Salaries and related expenses 1,789 1,158 Rent and maintenance 114 106 Share-based compensation 137 84 Other expenses 400 257 6,334 4,684

General and Administrative (Tab

General and Administrative (Tables)	12 Months Ended
	Dec. 31, 2021
General and Administrative Expense [Abstract]
Schedule of General and Administrative	Year ended Year ended December 31, December 31, 2021 2020 USD thousands USD thousands Salaries and related expenses 943 334 Professional services 1,695 828 Share-based compensation 1,882 46 Fees to Directors 244 - Insurance 1,024 6 Rent and maintenance 29 24 Other expenses 216 50 6,033 1,288

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Significant Components of the Company's Deferred Tax Asset	In respect of: December 31, December 31, 2021 2020 USD thousands USD thousands Net operating loss carry-forwards 33,396 4,874 Share-based compensation expense 1,147 57 Research and development costs 1,449 1,244 Other 38 25 Gross deferred tax assets 36,030 6,200 Less - Valuation allowance ( 36,030 ) (6,200) Net deferred tax assets - -
Schedule of Roll Forward of Valuation Allowance	E. Roll forward of valuation allowance Balance at January 1, 2020 $ 4,248 Currency transaction loss 583 Income tax expense 1,369 Balance at December 31, 2020 $ 6,200 Currency transaction loss 2,425 Tax assets acquired through merger 24,535 Income tax expense 2,870 Balance at December 31, 2021 $ 36,030
Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense	A reconciliation of the Company’s theoretical income tax expense to actual income tax expense is as follows: December 31, December 31, 2021 2020 USD thousands USD thousands Loss before income taxes ( 12,478 ) (5,951 ) Statutory tax rate 23 % 23 % Theoretical tax benefit ( 2,870 ) (1,369 ) Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards 2,870 1,369 Actual income tax expense - -

Related Parties Balances and _2

Related Parties Balances and Transactions (Tables)	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Schedule of Related Party Payables	The following Related Party payables are included in the consolidated Balance Sheets: December 31, December 31, 2021 2020 USD thousands USD thousands Employee and related expenses 278 214 Accrued expenses 72 3 350 217
Schedule of Transaction With Related Parties	The following transactions with related parties are included in the consolidated Statements of Operations: Year ended Year ended December 31, December 31, 2021 2020 USD thousands USD thousands Salaries and related expenses 1,255 605 Share-based payments 1,775 91 Professional Services 244 45 Research and development 36 36 3,310 777

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable to Ordinary Shareholders (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of basic and diluted net loss per share attributable to ordinary shareholders for the periods presented: Year ended Year ended December 31 December 31 2021 2020 In USD thousands, except share and per share data Numerator: Net loss 12,478 5,951 Denominator: Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted 207,468,650 136,755,498 Net loss per share attributable to ordinary shareholders, basic and diluted 0.060 0.044
Schedule of Weighted Average Number of Shares Excluded From Computation of Diluted Net Loss Per Share	The potential number of weighted-average ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented since including them would have been anti-dilutive are as follows: Year ended Year ended December 31 December 31 2021 2020 Number of shares Outstanding options to purchase ordinary shares 27,003,260 10,455,580

General (Details)

General (Details)	Mar. 16, 2021shares	Dec. 14, 2020
Restructuring Cost and Reserve [Line Items]
Reverse stock split conversion ratio	4
Merger agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company [Member]
Restructuring Cost and Reserve [Line Items]
Number of ordinary shares represented by each ADS (in shares)	20
Number of ADS issued and outstanding after the merger	12.86
Merger agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company [Member] | Former Chemomab Security Holders [Member]
Restructuring Cost and Reserve [Line Items]
Shareholding percentage immediately following the merger		90.00%
Merger agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company [Member] | Security holders of Anchiano as of immediately prior to the merger [Member]
Restructuring Cost and Reserve [Line Items]
Shareholding percentage immediately following the merger		10.00%

General (Schedule of net assets

General (Schedule of net assets acquired based on their estimated fair value) (Details) $ in Thousands	Mar. 16, 2021USD ($)
NATURE OF OPERATIONS
Cash and cash equivalents	$ 2,427
Asset held for sale	1,000
Prepaid and other assets	236
Accrued liabilities	(1,187)
Net acquired assets	$ 2,476

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Percentage of monthly deposits rate	8.33%
Severance costs	$ 116	$ 77

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Schedule of Annual rates of Depreciation) (Details)	12 Months Ended
	Dec. 31, 2021
Computers [Member]
Property, Plant and Equipment [Line Items]
Annual rates of depreciation	33.00%
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Annual rates of depreciation	10.00%
Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Annual rates of depreciation	7.00%
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Annual rates of depreciation	over the shorter of the lease term or the estimated useful life of the improvement

Cash and Cash Equivalents (Deta

Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Cash and Cash Equivalents	$ 15,186	$ 11,674
ILS [Member]
Cash and Cash Equivalents	1,116	95
USD [Member]
Cash and Cash Equivalents	10,720	11,526
Other currencies [Member]
Cash and Cash Equivalents	$ 3,350	$ 53

Other Receivables and Prepaid_3

Other Receivables and Prepaid Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Prepaid Expense and Other Assets [Abstract]
Government institutions	$ 179	$ 74
Prepaid expenses	1,348	67
Other accounts receivable and prepaid expenses, Total	$ 1,527	$ 141

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Cost	$ 464	$ 225
Less - accumulated depreciation	(107)	(73)
Property Plant And Equipment Net	357	152
Computers [Member]
Property, Plant and Equipment [Line Items]
Cost	43	31
Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Cost	27	16
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Cost	364	159
Website Development [Member]
Property, Plant and Equipment [Line Items]
Cost	14	14
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Cost	$ 16	$ 5

Leases (Narrative) (Details)

Leases (Narrative) (Details) ₪ in Thousands, $ in Thousands	1 Months Ended			12 Months Ended
	Oct. 24, 2021USD ($)	May 31, 2020USD ($)	May 31, 2020ILS (₪)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 12, 2021USD ($)
Lessee, Lease, Description [Line Items]
Lease expiry date	Oct. 31, 2024	May 31, 2023	May 31, 2023
Lease term	3 years	3 years	3 years
Annual rent and management fees	$ 132	$ 71
Bank guarantees to property owner	$ 86	$ 49
Operating right-of-use assets and operating lease liabilities				$ 345	$ 343	$ 345
Decrease in the carrying amount of the right-of-use asset due to impairment				$ 345	$ 500
Incremental borrowing rate based on credit rating				5.20%	5.20%
ILS [Member]
Lessee, Lease, Description [Line Items]
Bank guarantees to property owner | ₪			₪ 170

Leases (Schedule of Maturity of

Leases (Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases) (Details) $ in Thousands	Dec. 31, 2021USD ($)
Lessee Disclosure [Abstract]
2022	$ 121
2023	133
2024	117
Total future minimum lease payments	371
Less imputed interest:	(28)
Present value of operating lease liabilities	$ 343

Commitments and Contingent Li_2

Commitments and Contingent Liabilities (Details) € in Thousands, ₪ in Thousands, $ in Thousands	1 Months Ended			6 Months Ended	12 Months Ended
	May 31, 2020USD ($)	May 31, 2020ILS (₪)	Jun. 30, 2015EUR (€)	Nov. 30, 2021EUR (€)	Dec. 31, 2022USD ($)	Dec. 31, 2022ILS (₪)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)
Other Commitments [Line Items]
Decsription of occurrence for payments							upon the occurrence of either (i) closing of a public offering of the ordinary shares of Chemomab; or (ii) a Change of Control Transaction, Chemomab shall pay the Fund a cash payment equal to one percent (1%) of the proceeds raised by Chemomab in its initial public offering, or 1% of the consideration received by Chemomab or its shareholders at the closing of a Change of Control Transaction (after deduction of amounts paid as liquidation preference to the shareholders of Chemomab on account of their investment in Chemomab , if any), but in any event not more than USD 3,000 thousand.
Maximum percentage of payments of royalties (as a percent)							100.00%
Cumulative amounts of grants received							$ 1,227
Royality expenses							2,590	$ 1,177
Bank restricted deposit							$ 55
Euro [Member]
Other Commitments [Line Items]
Payment for licensed agreement | €			€ 1,200	€ 5,831
Payment on commencement of agreement | €			€ 600
New Drug Application and Biological License Application [Member]
Other Commitments [Line Items]
Description of application payment for licensed product							USD 100 thousand upon submission of a New Drug Application (“NDA”), Biological License Application (“BLA”) or equivalent for each Licensed Product to the United States Food and Drug Administration (“FDA”), USD 100 thousand upon submission of similar application for each Licensed Product to an equivalent foreign regulatory agency in Europe and one hundred thousand dollars upon submission of similar application for each Licensed Product to an equivalent foreign regulatory agency in Asia. Payment in the aggregate shall not be more than USD 300 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once;
Royalty payments on sale of product (as a percent)							3.00%
FDA or equivalent agency marketing approval [Member]
Other Commitments [Line Items]
Description of application payment for licensed product							USD 200 thousand upon the grant of FDA or equivalent agency marketing approval in Europe and/or Asia for each Licensed Product. Payment in the aggregate shall not be more than USD 600 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once.
2020 Lien [Member]
Other Commitments [Line Items]
Lien on bank deposit	$ 49
2020 Lien [Member] | Forecast [Member]
Other Commitments [Line Items]
Lien on bank deposit					$ 86
2020 Lien [Member] | ILS [Member]
Other Commitments [Line Items]
Lien on bank deposit | ₪		₪ 170
2020 Lien [Member] | ILS [Member] | Forecast [Member]
Other Commitments [Line Items]
Lien on bank deposit | ₪						₪ 269

Share Capital (Narrative) (Deta

Share Capital (Narrative) (Details) $ / shares in Units, $ in Thousands

Mar. 15, 2021USD ($)

Apr. 30, 2021USD ($)

Mar. 23, 2021USD ($)$ / sharesshares

May 30, 2020USD ($)

Nov. 30, 2019USD ($)

Sep. 30, 2019USD ($)

Dec. 31, 2020USD ($)

Dec. 31, 2021USD ($)$ / sharesshares

Dec. 31, 2020shares

May 30, 2020₪ / sharesshares

Nov. 30, 2019₪ / sharesshares

Sep. 30, 2019₪ / sharesshares

Sale Of Stock [Line Items]

Options to purchase ADS cancelled

1,712,275

10,804

2015 plan [Member]

Sale Of Stock [Line Items]

Number of ADSs issued

73,776

Number of stock option ADSs reversed for issuance

1,422,153

Number of ADSs options issuable outstanding

1,326,723

Number of ADSs vested and exercisable

452,230

Weighted average exercise price | $ / shares

$ 2.75

Options to purchase ADS cancelled

35,653

Series C Preferred Stock [Member]

Sale Of Stock [Line Items]

Preferred shares issued

34,130

130,831

Preferred shares par value | ₪ / shares

₪ 0.01

₪ 0.01

Proceeds from preferred shares | $

$ 3,000

$ 500

$ 11,484

Investors [Member]

Sale Of Stock [Line Items]

Proceeds from exercise of warrants | $

$ 1,250

Investors [Member] | Series C Preferred Stock [Member]

Sale Of Stock [Line Items]

Preferred shares issued

34,130

Preferred shares par value | ₪ / shares

₪ 0.01

Proceeds from preferred shares | $

$ 3,000

The Private Placement [Member]

Sale Of Stock [Line Items]

Proceeds from sale of ADS's | $

$ 45,500

$ 4,500

Number of ADSs issued

261,929

Number of warrants purchase ADS's

2,619,270

Share price per share | $ / shares

$ 17.35

ATM agreement [Member]

Sale Of Stock [Line Items]

Proceeds from sale of ADS's | $

$ 75,000

$ 15,917

Number of ADSs issued

699,806

Share price per share | $ / shares

$ 22.75

Share Capital (Share-based comp

Share Capital (Share-based compensation expenses) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expenses	$ 2,019	$ 130
Research and development expenses [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expenses	137	84
General and administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expenses	$ 1,882	$ 46

Share Capital (Summary of numbe

Share Capital (Summary of number and weighted average exercise prices of option) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Weighted Average Exercise Price
Outstanding at the beginning	$ 0.07	$ 0.07
Exercise	0.08
Forfeited	1.25	0.07
Granted	0.62	0.08
Outstanding at the end	$ 0.38	$ 0.07	$ 0.07
Number of options
Outstanding at the beginning	10,455,580	8,072,704
Acquired in Merger	609,535
Exercise	(134,220)
Forfeited	(1,712,275)	(10,804)
Granted	17,784,640	2,393,680
Outstanding at the end	27,003,260	10,455,580	8,072,704
Weighted Average Remaining Contractual Life in Years
Outstanding	8 years 1 month 13 days	7 years 9 months 18 days	8 years 1 month 2 days
Granted	9 years 9 months 14 days	9 years 9 months 7 days

Share Capital (Summary of assum

Share Capital (Summary of assumptions used to calculate the fair value of the options) (Details)	12 Months Ended
	Dec. 31, 2021$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility, minimum	65.93%	[1]
Expected volatility, maximum	70.88%	[1]
Risk-free interest rate, minimum	1.36%	[2]
Risk-free interest rate, maximum	1.64%	[2]
Dividend yield	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average share price (in U.S. dollar)	$ 9.44	[3]
Exercise price (in U.S. dollar)	$ 9.44
Expected life of options (in years)	5 years 8 months 23 days	[4]
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average share price (in U.S. dollar)	$ 27.26	[3]
Exercise price (in U.S. dollar)	$ 27.26
Expected life of options (in years)	6 years 3 months 10 days	[4]
[1]	Expected volatility is based on historical volatility over the most recent period commensurate with the expected
[2]	The risk-free rate for the expected term of the options is based on the Black-Scholes option-pricing model on the
[3]	The weighted average share price is based on the Company’s ordinary share valuation as at the grant date.
[4]	Expected life for the periods presented was determined according to the simplified method since, at the date of

Research and Development (Sched

Research and Development (Schedule of Research and Development) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Research and Development [Abstract]
Consultants and subcontractors	$ 3,894	$ 3,079
Salaries and related expenses	1,789	1,158
Rent and maintenance	114	106
Share-based compensation	137	84
Other expenses	400	257
Total	$ 6,334	$ 4,684

General and Administrative (Sch

General and Administrative (Schedule of General and Administrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
General and Administrative Expense [Abstract]
Salaries and related expenses	$ 943	$ 334
Professional services	1,695	828
Share-based compensation	1,882	46
Fees to Directors	244
Insurance	1,024	6
Rent and maintenance	29	24
Other expenses	216	50
Total	$ 6,033	$ 1,288

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Israel [Member]
Income Tax Disclosure [Line Items]
Corporate tax rate (as a percent)	23.00%
Capital losses carryforwards	$ 143	$ 21
U.S. [Member] | Federal [Member]
Income Tax Disclosure [Line Items]
Corporate tax rate (as a percent)	21.00%

Income Taxes (Schedule of Signi

Income Taxes (Schedule of Significant Components of the Company's Deferred Tax Asset) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Deferred taxes
Net operating loss carry-forwards	$ 33,396	$ 4,874
Share-based compensation expense	1,147	57
Research and development costs	1,449	1,244
Other	38	25
Gross deferred tax assets	36,030	6,200
Less - valuation allowance	(36,030)	(6,200)	$ (4,248)
Net deferred tax assets
Net change in the total valuation allowance	$ 2,600

Income Taxes (Schedule of Roll

Income Taxes (Schedule of Roll Forward of Valuation Allowance) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Balance at January 1	$ 6,200	$ 4,248
Currency transaction loss	2,425	583
Tax assets acquired through merger	24,535
Income tax expense	2,870	1,369
Balance at December 31	$ 36,030	$ 6,200

Income Taxes (Schedule of Recon

Income Taxes (Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Theoretical tax benefit on the above amount Decrease (increase) in tax refund resulting from:
Loss before income tax	$ (12,478)	$ (5,951)
Statutory tax rate	23.00%	23.00%
Theoretical tax benefit	$ (2,870)	$ (1,369)
Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards	2,870	1,369
Actual income tax expense

Related Parties Balances and _3

Related Parties Balances and Transactions (Schedule of Related Party Payables) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Employee and related expenses	$ 653	$ 438
Accrued expenses	555	715
Related Party [Member]
Related Party Transaction [Line Items]
Employee and related expenses	278	214
Accrued expenses	72	3
Related Party Payables	$ 350	$ 217

Related Parties Balances and _4

Related Parties Balances and Transactions (Schedule of Transaction With Related Parties) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Related Party Transactions [Abstract]
Salaries and related expenses	$ 1,255	$ 605
Share-based payments	1,775	91
Professional Services	244	45
Research and development	36	36
Total related party expenses	$ 3,310	$ 777

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Computation of Basic and Diluted Net Loss) (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020
Earnings Per Share [Abstract]
Net loss		$ 12,478	$ 5,951
Denominator:
Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted	[1]	207,468,650	136,755,498
Net loss per share attributable to ordinary shareholders, basic and diluted		$ 0.060	$ 0.044
[1]	Number of shares has been retroactively adjusted to reflect the share reverse split effected on March 16, 2021 (refer to Note 1)

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Weighted Average Number of Shares) (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Stock Options [Member]
Outstanding options to purchase ordinary shares	27,003,260	10,455,580